Clinical Flow Cytometry

Jul 15, 20150 likes188 views

KCAS provides clinical flow cytometry services to support biologics and small molecule development. Their experienced scientists offer custom assay development and validation as well as sample processing and consulting for a variety of applications including pharmacodynamic assays, live cell assays, PBMC isolation, mechanism of action studies, and biomarker assays. KCAS has experience measuring immune cell subsets such as T cells, B cells, macrophages, and dendritic cells to monitor biologics and the immune system for therapeutic areas including allergy and asthma, autoimmune disease, infectious disease, oncology, stem cell enumeration, transplantation, and vaccines.

Capabilites
KCAS Bioanalytical & Biomarker Services | kcasbio.com | contact us: info@kcasbio.com
ClinicalFlowCytometryServices
KCAS�� ?ow cytometry team supports the clinical development for biologics and small molecules. Our experienced
scientists provide custom assay development, validation, sample processing and consulting services for a wide
variety of applications. We pride ourselves on being innovative problem solvers and it��s our top priority to help
clients overcome challenges encountered while developing functional pharmacodynamic assays, live cell assays,
isolation of PBMCs, mechanism of action studies, and biomarker assays. Our ?ow cytometry experts can help with
designing the study, performing the assay, and delivering quality data.
Applications
Flow cytometry is a critical tool for monitoring biologics
and how they augment the immune system. At KCAS we
use the ?ow cytometer to monitor phenotype and
functionality of white blood cell subsets. Our ?ow
cytometry team has experience measuring a wide range
of cells, including T cells, B cells, macrophages/monocytes,
basophils, neutrophils, dendritic cells and proliferation
assays (BrdU assays).
Researchers utilize ?ow cytometry for the treatment
of patients across a broad range of diseases.
Therapeutic Areas of Expertise:
�� Allergy & Asthma
�� Autoimmune Disease
�� Infectious Disease
�� Detection of Minimal Residual Disease (MRD)
�� Oncology
�� Stem Cell Enumeration
�� Transplantation
�� Vaccines
Antigen Speci?c Functional Cells
Tetramer staining and intracellular cytokines
IFN-��, TNF-��, IL-2, IL-4, IL-17
TBNK (T cell, B cell, & NK cell) Panel
CD3, CD4, CD8, CD16/56, CD19, CD45
T Cell Panels
T Regulatory Cells: CD45, CD4, CD25, CD127
Cytotoxic T Cells: CD3, CD8, CD107
B Cell Panels
Activated B Cells: CD45, CD19, CD20, CD69
Na?ve B Cells: CD45, CD19, CD20, CD27neg
Memory B Cells: CD45, CD19, CD20, CD27
Stem Cell Enumeration
CD45, CD34, 7-ADD
Leukemia & Lymphoma Markers
CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b,
CD11c, CD13, CD14, CD15, CD16, CD19, CD20,
CD23, CD33, CD34, CD38, CD41, CD45, CD56,
CD64, CD71, CD117, CD138, CD235a, FMC-7,
HLA-DR, kappa, lambda
Toll Like Receptors (TLRs)
Intracellular TLRs: TLR-3,-8,-9
Extracellular TLRs: TLR-1,-2,-4,-5,-6
Activated Basophils
CD45, surface IgE, CD63, CD203c
Cytokines*
Interleukin (IL)-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10,
IL-12, IL-13, IL-17, IL-18, IL-23, IFN-��, TNF-��, TGF-��
*Performed by Meso Scale Discovery Multiplex or ELISA
Diseases
Flow Cytometry & Biomarkers
Bioanalytical & Biomarker Services

The MultiOmyx Tumor Infiltrating Lymphocyte Panel provides comprehensive immunophenotyping from a single FFPE slide. It evaluates 12 key immune cell markers to identify immune checkpoint targets and characterize immune cell types and locations in the tumor microenvironment. Unlike serial sections, it analyzes all markers on a single slide. Advanced algorithms provide quantitative expression data, co-expression, and localization of markers at the individual cell level. The panel is offered by Clarient, which is CAP accredited and CLIA certified to ensure quality.

ALETA CNS metastasis program 8 July 2020Paul D. Rennert

Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell ProteinsMerck Life Sciences

Watch the presentation of this webinar here: https://bit.ly/3b3Tbcd Measurement of host cell proteins is vital to ensuring a biotherapy's purity and a patient's safety. Biotherapies treat diseases with products produced by living organisms, as a result, host cell components must be characterized and controlled. We'll review new methods within product characterization for detection. Trace amounts of host cell proteins can be present after the production and purification of any biopharmaceutical. Detection of these species requires highly specific techniques to accurately quantify even low levels of contamination. Host cell protein impurities, present at PPM-levels in biotherapies, are a major immunogenicity risk because they can elicit an unpredictable immune response in patients. Their complex and diverse nature makes them challenging to detect or monitor. With acceptance criteria for host residual DNA usually set at a very low level (often =1.0 pg of DNA per mg of drug substance), effective removal techniques and sensitive methods of detection are critical. Antibody-based techniques, like the enzyme-linked immunosorbent assay (ELISA), have been used to assess the HCP load of biotherapeutics before and after process changes. However, these techniques do not necessarily detect qualitative changes in the HCP population. In this webinar, we will discuss how mass spectrometry (MS)-based approaches coupled with ELISA methods help detect qualitative and quantitative differences in HCP populations. In this webinar, you will learn: ? Comprehensive HCP ID and semi-quantitation ? HC agnostic process ? Creation of process specific database ? Differential clearance of specific HCPs throughout purification steps ? Monitoring of problematic species e.g. immunogenic (PLBL2), lipases and proteases ? Explanation about why 90% of BLAs filed included this HCP MS data

Tumor immunityShoaib Irfan

This document discusses tumor immunity and tumor antigens. It describes the adaptive and innate immune system, including lymphocytes like T cells, B cells, and NK cells. It then classifies tumor antigens based on their expression patterns and molecular structures. Several types of tumor antigens are outlined, including products of mutated genes, oncofetal antigens, and antigens produced by oncogenic viruses. The immune response to tumors via cellular and humoral immunity is also summarized. Mechanisms by which tumor cells can evade the immune system are described. The document concludes by covering immunodiagnosis and different immunotherapy approaches.

Wong raymond symposium2016_presentchristinamcsher

The document summarizes recent developments in cancer immunotherapy, focusing on immune checkpoint blockade and the potential role of mesenchymal stem cells. It notes that between 2011-2016, the FDA approved several immune checkpoint inhibitors (targeting PD-1, PD-L1, CTLA-4) for various cancer types including melanoma, lung cancer, kidney cancer, and Hodgkin's lymphoma. While these drugs have shown success, many patients still do not respond. The document discusses using engineered mesenchymal stem cells to deliver immunotherapeutic agents directly to tumors, with the goal of overcoming adaptive immune resistance in the tumor microenvironment and improving response rates to immunotherapy.

ESMO 2020 Abstract Analysis - BioTrack Pranay Madan

This document summarizes key information from 1,812 cancer research abstracts analyzed on the BioTrack platform. BioTrack allows users to aggregate data from multiple sources, automatically annotate and rank abstracts based on preferences, and enable sharing of insights with a team. The summary highlights the most frequently mentioned biomarkers, technologies, applications, therapeutic areas, and companies across the abstracts.

3768 rennertPaul D. Rennert

1) CAR T cells specific for CD19 have shown remarkable success in treating blood cancers but have had limited effect on solid tumors which lack the CD19 antigen. 2) The IMPACT technology uses fusion proteins containing the extracellular domain of CD19 linked to single-chain antibodies targeting other antigens to bridge CAR19 T cells to solid tumors. 3) Experiments showed CAR19 T cells redirected by a CD19-anti-HER2 fusion protein were cytotoxic against HER2-positive ovarian cancer cells in vitro, demonstrating the IMPACT technology can redirect CAR T cells to new tumor targets through antigen bridging.

Global manufacturing of car t cell therapyMQ73

The document discusses the global manufacturing of CAR T cell therapy. It describes the multi-step process of producing CAR T cells, including removing T cells from a patient's blood via leukapheresis, enriching and activating the T cells, transducing them with a lentiviral vector encoding the CAR, and expanding the CAR T cells in bioreactors. As CAR T cell therapy moves to larger clinical trials and more patients, ensuring consistent high-quality manufacturing at multiple sites globally while meeting regulatory requirements is important. The use of a stable, high-quality lentiviral vector produced in large batches can help standardize the cell processing.

Epi tect methylation qpcr arrays 2013Elsa von Licy

The document describes the EpiTect Methyl II PCR Array System for analyzing DNA methylation. It provides an overview of the system which enables pathway or disease-focused profiling of regional DNA methylation using optimized kits, assays, and data analysis templates. The system offers a complete solution for DNA methylation analysis from sample isolation through data analysis. Key advantages include its ability to simultaneously analyze methylation of many genes, compatibility with standard qPCR instruments, and generation of results comparable to bisulfite sequencing but with higher throughput and without the need for bisulfite conversion.

Rennert et al. ASH 2019 talkPaul D. Rennert

Tcr Technology - Creative BiolabsCreative-Biolabs

Enabling Cancer Immunotherapy: From Discovery to CombinationsDiscoverX Corporation

New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine a...PVI, PeerView Institute for Medical Education

The document discusses cancer immunotherapy and biomarkers. It provides diagrams of immune checkpoint blockade showing how CTLA-4 and PD-1 inhibitors work. It lists FDA-approved immune checkpoint inhibitors across different cancer types. Emerging immunotherapy targets and combinations are discussed, as well as current and emerging biomarkers like PD-L1 expression, MSI/MMR status, and tumor mutational burden that can help identify patients most likely to respond to immunotherapy. Practice aids provide more details on mechanisms, targets, and biomarker testing.

Car t cells - Chimeric antigen receptors (CARs)Qussai Abbas

Flow cytometry` dr nidhiDr Nidhi Rai Gupta

Flow cytometry allows for the analysis of physical and chemical properties of cells as they flow in a single file through an illuminated light path. It can be used to identify cell types based on relative size, granularity, and fluorescent marker expression. In this document, applications of flow cytometry are discussed, including immunophenotyping cells to identify antigen expression, cell sorting, DNA content analysis, and cell cycle analysis. Clinical uses in hematological malignancies, transplantation, and sepsis are also described. Key markers for identifying and classifying acute leukemias, including ALL, AML, and myelomonocytic leukemia are provided.

Nancytomique Wuhan Juin 2013OKCC/C3O and CREM/universit�� Lorraine

Chimeric Antigen Receptor (car) Technique-Creative BiolabsCreative-Biolabs

Fluorescent Activated Cell Sorting: Diagnosis of HIV InfectionAf Ashraf

Clusters of differentiation (CDs)Fawzia Abo-Ali

CD antigens, also known as clusters of differentiation, are cell surface proteins that are used to identify and characterize cell types. Over 371 CD markers have been identified that serve important functions like cell signaling. CD markers are analyzed using techniques like flow cytometry and help diagnose diseases like leukemia by identifying abnormal levels of specific CD antigens. Key CD markers have been identified for important immune cells like T cells, B cells, granulocytes, and stem cells. Immunophenotyping using CD markers is an important application in diagnosing diseases and monitoring treatment responses.

Molecular pathology of lymphoma by dr ramesh Ramesh Purohit

Lymphoma classification is based on the cell of origin (B-cell, T-cell, NK-cell). Molecular biology techniques including immunophenotyping and genetic studies are important for accurate diagnosis and classification. Immunophenotyping uses cell surface markers identified by clusters of differentiation (CD markers) to determine the cell lineage and stage of differentiation. Common CD markers for B-cells, T-cells, myeloid cells and other lineages are described. Molecular studies can identify genetic abnormalities that help classify specific lymphoma subtypes. Together these molecular techniques provide crucial information beyond what is visible by microscopy alone.

T cell activation assayCreative Biolabs

Antigen specific T cell activation assay is one of the technologies we can provide during the one-stop service which can activate CAR-T cells for further downstream research or clinical trials. T cell activation requires at least two signals to be fully activated. The first signal is provided by the interaction of T cell antigen-specific receptor and the antigen-major histocompatibility complex (MHC).? https://www.creative-biolabs.com/car-t/antigen-specific-t-cell-activation-assay.htm

Prof.dr.moh'd sorour bchmohammed4450

This document provides an overview of flow cytometry, including its principles, instrumentation, applications in hematology and oncology, and techniques for analyzing results. Flow cytometry works by passing single cells in a fluid stream through a laser beam, which detects cellular properties like size, structure, and antigen expression. It allows for multiparametric analysis of up to 12 parameters simultaneously on thousands of cells. Key applications include immunophenotyping of leukemias and lymphomas, DNA analysis, and monitoring of minimal residual disease.

PlOSone paperNaomi McReynolds

This research article demonstrates the use of Wavelength Modulated Raman Spectroscopy (WMRS) to identify major immune cell subsets in an unlabeled and non-fixed state. Using WMRS, the researchers were able to distinguish between CD4+ T lymphocytes, CD8+ T lymphocytes, and CD56+ Natural Killer cells from multiple donors with up to 96% specificity. They also distinguished between CD303+ plasmacytoid and CD1c+ myeloid dendritic cell subsets. This label-free method opens new opportunities for analyzing immune systems and developing diagnostic technologies without altering or damaging the cells.

HemaCare�� uƷ��ҪCOSMO BIO

HemaCare is a leading provider of apheresis products and services for biomedical research and cellular therapy. For over 39 years, they have collected over 250,000 apheresis procedures and provide blood cells and components from both healthy and disease state donors. Their products and services include human primary cells, tissues, preservation media, and cellular therapy solutions to support research from preclinical to clinical trials. HemaCare has a highly characterized donor database and state-of-the-art apheresis collection capabilities to provide customized collections. Their quality products include peripheral blood, bone marrow, cord blood, and stem/progenitor cells, as well as disease-specific primary cells and leukapaks.

Epiontis immune monitoring and companion diagnostics 2013TOKBSL

Epiontis introduces novel epigenetic immune cell markers that enable standardized immune monitoring from frozen whole blood or tissue samples. The markers allow precise quantification of immune cells using quantitative PCR targeting cell type-specific epigenetic modifications. The assays require small sample volumes and can measure a wide range of immune cell types from various sample types and storage conditions. Epiontis has extensive experience and quality management systems for clinical trial immune monitoring.

T cell and NK-cell neoplasmsAbdullah Hashish

This document discusses T-cell and NK-cell neoplasms. It begins by describing NK cells and their morphology as large granular lymphocytes that lack T-cell receptors and CD3 expression but express CD56 and CD16. The document then covers the various types of T-cell and NK-cell neoplasms including their morphology, immunophenotype, and genetics. Key neoplasms discussed are T-cell lymphoblastic leukemia/lymphoma, T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, and extranodal NK/T-cell lymphoma among others. The document provides details on the diagnostic criteria for each type of neoplasm.

CAR_T_Cells_Engineering for biomedical engineeringmdsumonali589

Basic principles of cancer immunotherapyMohamed Abdulla

dkNET-HIRN Webinar "T Cell Antigen Discovery: Experimental and Computational ...dkNET

dkNET New Investigator Pilot Program in Bioinformatics Awardee Seminar Series Co-Hosted with Human Islet Research Network (HIRN) Presenter: Alok V. Joglekar, Ph.D. Assistant Professor, Center for Systems Immunology and Department of Immunology, University of Pittsburgh School of Medicine Abstract T cells are key players in many autoimmune diseases including Type 1 Diabetes. T cell responses are highly antigen specific by virtue of their T cell receptors (TCRs), that recognize epitopes on target cells. The enormous diversity of TCRs in an immune response poses a challenge in studying them, particularly regarding their antigenic specificity. Several experimental approaches have been developed to identify T cell specificities, with a recent surge in cell-based assays. More recently, computational approaches to predict T cell specificity are being developed and show great promise. This webinar will provide an overview of the experimental and computational approaches to identify T cell antigens. Furthermore, we will highlight the research performed in the Joglekar lab towards applying these approaches for auto-antigen discovery in Type 1 Diabetes. Finally, we will project what the future of these approaches may be, particularly for studying autoimmune diseases.

More Related Content

What's hot (7)

Global manufacturing of car t cell therapyMQ73

Epi tect methylation qpcr arrays 2013Elsa von Licy

Rennert et al. ASH 2019 talkPaul D. Rennert

Tcr Technology - Creative BiolabsCreative-Biolabs

Enabling Cancer Immunotherapy: From Discovery to CombinationsDiscoverX Corporation

New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine a...PVI, PeerView Institute for Medical Education

Car t cells - Chimeric antigen receptors (CARs)Qussai Abbas

Global manufacturing of car t cell therapyMQ73

Epi tect methylation qpcr arrays 2013Elsa von Licy

Rennert et al. ASH 2019 talkPaul D. Rennert

Tcr Technology - Creative BiolabsCreative-Biolabs

Enabling Cancer Immunotherapy: From Discovery to CombinationsDiscoverX Corporation

New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine a...PVI, PeerView Institute for Medical Education

Car t cells - Chimeric antigen receptors (CARs)Qussai Abbas

Similar to Clinical Flow Cytometry (20)

Flow cytometry` dr nidhiDr Nidhi Rai Gupta

Nancytomique Wuhan Juin 2013OKCC/C3O and CREM/universit�� Lorraine

Chimeric Antigen Receptor (car) Technique-Creative BiolabsCreative-Biolabs

Fluorescent Activated Cell Sorting: Diagnosis of HIV InfectionAf Ashraf

Clusters of differentiation (CDs)Fawzia Abo-Ali

Molecular pathology of lymphoma by dr ramesh Ramesh Purohit

T cell activation assayCreative Biolabs

Prof.dr.moh'd sorour bchmohammed4450

PlOSone paperNaomi McReynolds

HemaCare�� uƷ��ҪCOSMO BIO

Epiontis immune monitoring and companion diagnostics 2013TOKBSL

T cell and NK-cell neoplasmsAbdullah Hashish

CAR_T_Cells_Engineering for biomedical engineeringmdsumonali589

Basic principles of cancer immunotherapyMohamed Abdulla

dkNET-HIRN Webinar "T Cell Antigen Discovery: Experimental and Computational ...dkNET

Gemei news in stem cellMarica Gemei

1. Flow cytometry can be used to identify and characterize stem cells using cell surface markers. Hematopoietic stem cells are one of the best characterized stem cells and can be identified using markers like CD34 and CD38. 2. Cancer stem cells have also been identified in several cancers including cancers of the brain, breast, colon, and prostate. Colon cancer stem cells can be identified as the CD133+CD44+ population and have an increased expression of CD66c. 3. Silencing of the CD66c marker in colon cancer cell lines results in decreased proliferation and tumorigenicity, demonstrating its importance in identifying the colon cancer stem cell population.

Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD);Flowcytometric...Dr Siddartha

Stem Cells 21 Medical Center Paul Collier

Cancer and ihc markersNilesh Kucha

This document discusses immunohistochemistry (IHC), which is used to identify tissue antigens through antigen-antibody interactions. It provides details on the IHC process, common antibodies and their targets, and tumor markers. IHC is useful for tumor diagnosis, narrowing differential diagnoses, and detecting unexpected diagnoses. The antibody panels discussed can help determine the primary site of cancers and differentiate between tumor types.

Advances-in-car-t-cell-therapy-research.pdfssuser54a9d9

This document discusses CAR-T cell therapy and provides an overview of the CAR-T cell development process. It describes the key steps in designing and engineering CAR-T cells, including validating the CAR construct, producing lentivirus, transducing T cells, and functionally validating the CAR-T cells through co-culture assays. Five CAR-T cell therapies have been approved by the FDA to treat certain cancers like lymphoma and multiple myeloma. While CAR-T therapy has had success, challenges remain in applying it to solid tumors due to tumor heterogeneity and the complex tumor microenvironment.

Flow cytometry` dr nidhiDr Nidhi Rai Gupta

Nancytomique Wuhan Juin 2013OKCC/C3O and CREM/universit�� Lorraine

Chimeric Antigen Receptor (car) Technique-Creative BiolabsCreative-Biolabs

Fluorescent Activated Cell Sorting: Diagnosis of HIV InfectionAf Ashraf

Clusters of differentiation (CDs)Fawzia Abo-Ali

Molecular pathology of lymphoma by dr ramesh Ramesh Purohit

T cell activation assayCreative Biolabs

Prof.dr.moh'd sorour bchmohammed4450

PlOSone paperNaomi McReynolds

HemaCare�� uƷ��ҪCOSMO BIO

Epiontis immune monitoring and companion diagnostics 2013TOKBSL

T cell and NK-cell neoplasmsAbdullah Hashish

CAR_T_Cells_Engineering for biomedical engineeringmdsumonali589

Basic principles of cancer immunotherapyMohamed Abdulla

dkNET-HIRN Webinar "T Cell Antigen Discovery: Experimental and Computational ...dkNET

Gemei news in stem cellMarica Gemei

Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD);Flowcytometric...Dr Siddartha

Stem Cells 21 Medical Center Paul Collier

Cancer and ihc markersNilesh Kucha

Advances-in-car-t-cell-therapy-research.pdfssuser54a9d9

More from KCAS Bioanalytical & Biomarker Services (7)

Validated Method ListKCAS Bioanalytical & Biomarker Services

The document lists new and under development analytical methods for various analytes in different biological matrices like plasma, serum, urine, etc. It provides the analyte, matrix, lower limit of quantification, unit of measurement, and analytical platform (LC-MS/MS, ELISA, HPLC, etc.) for over 100 methods. The methods cover therapeutic drug monitoring, toxicology testing, biomarker analysis, and more. New methods are fully validated, while those under development are still in the validation process.

Alkaline Hematin BiomarkerKCAS Bioanalytical & Biomarker Services

The document discusses a method called alkaline hematin for quantitatively measuring menstrual blood loss, which is commonly used as an endpoint in clinical trials for conditions like menorrhagia, endometriosis, and uterine fibroids. The method involves measuring the absorbance of hematin extracted from used feminine hygiene products. KCAS has validated this alkaline hematin assay according to FDA standards and has experience measuring over 137,000 samples from more than 10,000 menstrual cycles using this method. Their validated method and data have supported FDA approval for several drugs and devices.

Bioanalytical & Biomarker CapabilitiesKCAS Bioanalytical & Biomarker Services

KCAS Bioanalytical Services is a contract research organization that provides bioanalytical and immunoanalytical services to support pharmaceutical and biotechnology companies. They have over 35 years of experience producing reliable and high quality results for small molecule, large molecule, and biomarker analysis. Their services include method development, validation, sample analysis, and clinical trial support for global studies. They have state-of-the-art facilities and equipment, including multiple LC-MS/MS systems and immunoassay instruments located in a 33,000 square foot laboratory near Kansas City.

Clinical Sample Logistics & Long-Term StorageKCAS Bioanalytical & Biomarker Services

KCAS provides clinical sample logistics and long-term storage services to support clients' research and development programs. Their services include protocol guidance for sample collection and shipping, ensuring proper sample processing, providing supplies, designing customized databases, monitoring clinical sites, and long-term storage of samples in freezers at -20��C and -70��C with temperature monitoring and backup systems. They have over 35 years of experience in sample management and have successfully supported many large clinical studies.

Preclinical Flow CytometryKCAS Bioanalytical & Biomarker Services

KCAS' flow cytometry team supports assay development, validation, and sample processing for preclinical and clinical studies. They helped a client design and perform a pharmacodynamic assay to measure T cell, B cell, and NK cell counts in rats treated with an antibody therapeutic within 4 weeks. KCAS recommended using CD45 lymphocyte gating and BD Trucount tubes for absolute counts. Results showed preserved samples had less than 20% variability in cell counts and percentages compared to unpreserved samples over 5 days. KCAS successfully completed the study in under 4 weeks as requested by the client.

Small Molecule BioanalysisKCAS Bioanalytical & Biomarker Services

This document summarizes the bioanalytical services of KCAS including non-GLP method development and validation of assays in various biological matrices to support preclinical and clinical trials. It offers over 900 validated assays across all drug classes developed on 15 AB Sciex LC-MS/MS systems. Services also include method transfer, clinical trial material support, sample storage, chiral and biomarker analysis, and FDA compliant validations.

Tissue PK & Biomarker AnalysisKCAS Bioanalytical & Biomarker Services

KCAS successfully transferred and qualified a tissue biomarker assay for a client within an eight week timeline, two weeks ahead of schedule. They improved the assay's sensitivity and dilution linearity, resulting in cost savings. KCAS tested over 2,500 samples from three studies without any failed assays. KCAS has extensive experience developing, validating, and supporting tissue PK and biomarker assays for preclinical and clinical studies across various tissues and species.

Validated Method ListKCAS Bioanalytical & Biomarker Services

Alkaline Hematin BiomarkerKCAS Bioanalytical & Biomarker Services

Bioanalytical & Biomarker CapabilitiesKCAS Bioanalytical & Biomarker Services

Clinical Sample Logistics & Long-Term StorageKCAS Bioanalytical & Biomarker Services

Preclinical Flow CytometryKCAS Bioanalytical & Biomarker Services

Small Molecule BioanalysisKCAS Bioanalytical & Biomarker Services

Tissue PK & Biomarker AnalysisKCAS Bioanalytical & Biomarker Services

Recently uploaded (20)

4-PuroKalusugasan 2025 DM 2025-0024.pptxNashiedaLilangBuale

Diabetic Ketoacidosis (DKA) & Its Management ProtocolDr Anik Roy Chowdhury

psychosomaticdisorder and it's physiotherapy managementDr Shiksha Verma (PT)

HUMAN SEXUALITY AND SEXUAL RESPONCE CYCLEdaminipatel37

MORPHOLOGICAL FEATURES OF PNEUMONIA.....maheenmazhar021

This presentation provides a detailed exploration of the morphological and microscopic features of pneumonia, covering its histopathology, classification, and clinical significance. Designed for medical students, pathologists, and healthcare professionals, this lecture differentiates bacterial vs. viral pneumonia, explains lobar, bronchopneumonia, and interstitial pneumonia, and discusses diagnostic imaging patterns. ? Key Topics Covered: ? Normal lung histology vs. pneumonia-affected lung ? Morphological changes in lobar, bronchopneumonia, and interstitial pneumonia ? Microscopic features: Fibroblastic plugs, alveolar septal thickening, inflammatory cell infiltration ? Stages of lobar pneumonia: Congestion, Red hepatization, Gray hepatization, Resolution ? Common causative pathogens (Streptococcus pneumoniae, Klebsiella pneumoniae, Mycoplasma, etc.) ? Clinical case study with diagnostic approach and differentials ? Who Should Watch? This is an essential resource for medical students, pathology trainees, and respiratory health professionals looking to enhance their understanding of pneumonia��s morphological aspects.

Presentaci�� "Projecte Benestar". MWC 2025Badalona Serveis Assistencials

Renal Physiology - Regulation of GFR and RBFMedicoseAcademics

PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...ABHAY INSTITUTION

Personality theory is a collection of ideas that explain how a person's personality develops and how it affects their behavior. It also seeks to understand how people react to situations, and how their personality impacts their relationships. Key aspects of personality theory Personality traits: The characteristics that make up a person's personality. Personality development: How a person's personality develops over time. Personality disorders: How personality theories can be used to study personality disorders. Personality and environment: How a person's personality is influenced by their environment.

PRODUCTION OF HB VACCINE AND INTERFERONS BY rDNA - Copy.pptxkarishmaduhijod1

4. Cardiac cycle.pptx cardiovascular systemPooja Rani

DIAGNOSIS OF PREGNANCY PPT IN ALL TRIMESTERdaminipatel37

Correlation of vitamin D level with prediabetes status_Dr Ahmed Al Montasir_f...zilkerapurbo

ISPE Baseline PEG Volumen 7 Risk-Based Manufacture Pharmaceutical Products 2n...alokksharma18

MLS 208 - UNIT 1- Lecture Notes - ETANDO AYUK - SANU - Secured.pdfEswatini Medical Christian University - EMCU / Southern Nazarene University - SANU

FAO's Support Rabies Control in Bali_Jul22.pptxWahid Husein

BIOMECHANICS OF THE MOVEMENT OF THE SHOULDER COMPLEX.pptxdrnidhimnd

The shoulder complex acts as in coordinated fashion to provide the smoothest and greatest range of motion possible of the upper limb. Combined motion of GH and ST joint of shoulder complex helps in: Distribution of motion between other two joints. Maintenance of glenoid fossa in optimal position. Maintenance of good length tension Although some amount of glenohumeral motion may occur while the other shoulder articulations remain stabilized, movement of the humerus more commonly involves some movement at all three shoulder joints.

Endocarditis.pptxNandish Sannaiah

Stability of Dosage Forms as per ICH GuidelinesKHUSHAL CHAVAN

This presentation covers the stability testing of pharmaceutical dosage forms according to ICH guidelines (Q1A-Q1F). It explains the definition of stability, various testing protocols, storage conditions, and evaluation criteria required for regulatory submissions. Key topics include stress testing, container closure systems, stability commitment, and photostability testing. The guidelines ensure that pharmaceutical products maintain their identity, purity, strength, and efficacy throughout their shelf life. This resource is valuable for pharmaceutical professionals, researchers, and regulatory experts.

Biography of Dr. Vincenzo GiordanoDr. Vincenzo Giordano

Best Sampling Practices Webinar �C USP <797> Compliance & Environmental Monito...NuAire

Best Sampling Practices Webinar �C USP <797> Compliance & Environmental Monitoring Are your cleanroom sampling practices USP <797> compliant? This webinar, hosted by Pharmacy Purchasing & Products (PP&P Magazine) and sponsored by NuAire, features microbiology expert Abby Roth discussing best practices for surface & air sampling, data analysis, and compliance. ? Key Topics Covered: ?? Viable air & surface sampling best practices ?? USP <797> requirements & compliance strategies ?? How to analyze & trend viable sample data ?? Improving environmental monitoring in cleanrooms ? Watch Now: https://www.nuaire.com/resources/best-sampling-practices-cleanroom-usp-797 ? Stay informed��follow Abby Roth on LinkedIn for more cleanroom insights!

4-PuroKalusugasan 2025 DM 2025-0024.pptxNashiedaLilangBuale

Diabetic Ketoacidosis (DKA) & Its Management ProtocolDr Anik Roy Chowdhury

psychosomaticdisorder and it's physiotherapy managementDr Shiksha Verma (PT)

HUMAN SEXUALITY AND SEXUAL RESPONCE CYCLEdaminipatel37

MORPHOLOGICAL FEATURES OF PNEUMONIA.....maheenmazhar021

Presentaci�� "Projecte Benestar". MWC 2025Badalona Serveis Assistencials

Renal Physiology - Regulation of GFR and RBFMedicoseAcademics

PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...ABHAY INSTITUTION

PRODUCTION OF HB VACCINE AND INTERFERONS BY rDNA - Copy.pptxkarishmaduhijod1

4. Cardiac cycle.pptx cardiovascular systemPooja Rani

DIAGNOSIS OF PREGNANCY PPT IN ALL TRIMESTERdaminipatel37

Correlation of vitamin D level with prediabetes status_Dr Ahmed Al Montasir_f...zilkerapurbo

ISPE Baseline PEG Volumen 7 Risk-Based Manufacture Pharmaceutical Products 2n...alokksharma18

MLS 208 - UNIT 1- Lecture Notes - ETANDO AYUK - SANU - Secured.pdfEswatini Medical Christian University - EMCU / Southern Nazarene University - SANU

FAO's Support Rabies Control in Bali_Jul22.pptxWahid Husein

BIOMECHANICS OF THE MOVEMENT OF THE SHOULDER COMPLEX.pptxdrnidhimnd

Endocarditis.pptxNandish Sannaiah

Stability of Dosage Forms as per ICH GuidelinesKHUSHAL CHAVAN

Biography of Dr. Vincenzo GiordanoDr. Vincenzo Giordano

Best Sampling Practices Webinar �C USP <797> Compliance & Environmental Monito...NuAire

Clinical Flow Cytometry

1. Capabilites KCAS Bioanalytical & Biomarker Services | kcasbio.com | contact us: info@kcasbio.com ClinicalFlowCytometryServices KCAS�� ?ow cytometry team supports the clinical development for biologics and small molecules. Our experienced scientists provide custom assay development, validation, sample processing and consulting services for a wide variety of applications. We pride ourselves on being innovative problem solvers and it��s our top priority to help clients overcome challenges encountered while developing functional pharmacodynamic assays, live cell assays, isolation of PBMCs, mechanism of action studies, and biomarker assays. Our ?ow cytometry experts can help with designing the study, performing the assay, and delivering quality data. Applications Flow cytometry is a critical tool for monitoring biologics and how they augment the immune system. At KCAS we use the ?ow cytometer to monitor phenotype and functionality of white blood cell subsets. Our ?ow cytometry team has experience measuring a wide range of cells, including T cells, B cells, macrophages/monocytes, basophils, neutrophils, dendritic cells and proliferation assays (BrdU assays). Researchers utilize ?ow cytometry for the treatment of patients across a broad range of diseases. Therapeutic Areas of Expertise: �� Allergy & Asthma �� Autoimmune Disease �� Infectious Disease �� Detection of Minimal Residual Disease (MRD) �� Oncology �� Stem Cell Enumeration �� Transplantation �� Vaccines Antigen Speci?c Functional Cells Tetramer staining and intracellular cytokines IFN-��, TNF-��, IL-2, IL-4, IL-17 TBNK (T cell, B cell, & NK cell) Panel CD3, CD4, CD8, CD16/56, CD19, CD45 T Cell Panels T Regulatory Cells: CD45, CD4, CD25, CD127 Cytotoxic T Cells: CD3, CD8, CD107 B Cell Panels Activated B Cells: CD45, CD19, CD20, CD69 Na?ve B Cells: CD45, CD19, CD20, CD27neg Memory B Cells: CD45, CD19, CD20, CD27 Stem Cell Enumeration CD45, CD34, 7-ADD Leukemia & Lymphoma Markers CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD41, CD45, CD56, CD64, CD71, CD117, CD138, CD235a, FMC-7, HLA-DR, kappa, lambda Toll Like Receptors (TLRs) Intracellular TLRs: TLR-3,-8,-9 Extracellular TLRs: TLR-1,-2,-4,-5,-6 Activated Basophils CD45, surface IgE, CD63, CD203c Cytokines* Interleukin (IL)-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, IL-18, IL-23, IFN-��, TNF-��, TGF-�� *Performed by Meso Scale Discovery Multiplex or ELISA Diseases Flow Cytometry & Biomarkers Bioanalytical & Biomarker Services

�ݺ�ߣ

Clinical Flow Cytometry

Recommended

More Related Content

What's hot (7)

Similar to Clinical Flow Cytometry (20)

More from KCAS Bioanalytical & Biomarker Services (7)

Recently uploaded (20)

Clinical Flow Cytometry